{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:04:13Z","timestamp":1772913853968,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metformin-induced lactic acidosis with acute kidney injury is rare but well known. Here we report a case of a Japanese patient taking metformin who experienced severe acute renal failure accompanied with significantly elevated metformin plasma concentrations and signs of lactic acidosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 60-year-old Japanese man with type II diabetes, who was taking metformin (500\u00a0mg three times a day) along with several other medications, visited the emergency department with dizziness, malaise, and oliguria. The initial laboratory test results showed elevated levels of serum creatinine and blood urea nitrogen, although his renal function was normal approximately 2\u00a0weeks earlier. His lactate level was raised (4.27\u00a0mmol\/L), and he was diagnosed with lactic acidosis. Considering the low creatinine clearance and elevated urinary albumin\/serum creatinine ratio, urinary <jats:italic>N<\/jats:italic>-acetyl-\u03b2-<jats:sc>d<\/jats:sc>-glucosaminidase level, and \u03b22-microglobulin level, the patient was further diagnosed with AKI (in other words, acute tubular necrosis). A renal biopsy performed on day 3 after admission revealed renal tubular epithelium necrosis, supporting this diagnosis. The patient underwent intermittent hemodialysis until he was discharged on day 13. The metformin concentrations on days 3, 5, and 7 were 8.95, 2.58, and 0.16\u00a0\u03bcg\/mL, respectively, which is significantly higher than the maximal steady-state concentration of metformin at the recommended dosage (approximately 1\u00a0\u03bcg\/mL). The calculated pharmacokinetic parameters of metformin suggested poor renal excretion and a low distribution volume at higher metformin levels. Other possible acute kidney injury-causing factors included dehydration, alcohol consumption, and the use of an angiotensin receptor blocker or SGLT2 inhibitor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first reported case of acute kidney injury possibly caused by high levels of metformin with lactic acidosis in a patient treated with the recommended metformin dose. Thus, the development of metformin-induced acute kidney injury should be considered for patients with several acute kidney injury risk factors who are taking metformin.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04136-0","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:02:15Z","timestamp":1694822535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Daily dose of metformin caused acute kidney injury with lactic acidosis: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Maho","family":"Ariga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichiro","family":"Hagita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Soda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Oida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Teramachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoyuki","family":"Kitaichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,16]]},"reference":[{"key":"4136_CR1","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G Zhou","year":"2001","unstructured":"Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et\u00a0al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167\u201374.","journal-title":"J Clin Invest"},{"key":"4136_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13256-018-1809-6","volume":"12","author":"K Suzuki","year":"2018","unstructured":"Suzuki K, Okada H, Yoshida S, Okamoto H, Suzuki A, Suzuki K, et\u00a0al. Effect of high-flow high-volume-intermittent hemodiafiltration on metformin-associated lactic acidosis with circulatory failure: a case report. J Med Case Rep. 2018;12:280.","journal-title":"J Med Case Rep"},{"key":"4136_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/ajcp\/80.4.484","volume":"80","author":"D Luft","year":"1983","unstructured":"Luft D, Deichsel G, Schm\u00fclling RM, Stein W, Eggstein M. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol. 1983;80:484\u20139.","journal-title":"Am J Clin Pathol"},{"key":"4136_CR4","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1097\/CCM.0000000000001002","volume":"43","author":"DP Calello","year":"2015","unstructured":"Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, et\u00a0al. Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med. 2015;43:1716\u201330.","journal-title":"Crit Care Med"},{"key":"4136_CR5","first-page":"35","volume":"7","author":"M Abdessadek","year":"2015","unstructured":"Abdessadek M, Tadmori AE, Attari AE, Diarra M, Magoul R, Ajdi F, et\u00a0al. Simple HPLC-UV method for determination of metformin in human plasma and erythrocytes application to therapeutic drug monitoring. Int J Pharm Pharm Sci. 2015;7:35\u20139.","journal-title":"Int J Pharm Pharm Sci"},{"key":"4136_CR6","unstructured":"U.S. Department of Health and Human Services. Bioanalytical method validation guidance for industry (May 2018). https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 13 Dec 2021."},{"key":"4136_CR7","first-page":"439","volume":"47","author":"H Iwai","year":"2004","unstructured":"Iwai H, Ohno Y, Itoh H, Endo T, Komaki K, Ishii S, et\u00a0al. Type 2 diabetes mellitus with lactic acidosis and acute renal failure induced by metformin overdose in suicide. J Japan Diab Soc. 2004;47:439\u201345.","journal-title":"J Japan Diab Soc"},{"key":"4136_CR8","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1111\/bcp.13582","volume":"84","author":"AL Chiew","year":"2018","unstructured":"Chiew AL, Wright DFB, Dobos NM, McArdle K, Mostafa AA, Newth A, et\u00a0al. \u201cMassive\u201d metformin overdose. Br J Clin Pharmacol. 2018;84:2923\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"4136_CR9","volume":"10","author":"W Chowdhury","year":"2018","unstructured":"Chowdhury W, Lodhi MU, Syed IA, Ahmed U, Miller M, Rahim M. Metformin-induced lactic acidosis: a case study. Cureus. 2018;10: e2152.","journal-title":"Cureus"},{"key":"4136_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5301\/jn.5000166","volume":"26","author":"A Rocha","year":"2013","unstructured":"Rocha A, Almeida M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol. 2013;26:55\u201360.","journal-title":"J Nephrol"},{"key":"4136_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1172\/JCI37829","volume":"119","author":"C Brooks","year":"2009","unstructured":"Brooks C, Wei Q, Cho SG, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest. 2009;119:1275\u201385.","journal-title":"J Clin Invest"},{"key":"4136_CR12","doi-asserted-by":"publisher","first-page":"8742","DOI":"10.18632\/aging.103095","volume":"12","author":"Q Pan","year":"2020","unstructured":"Pan Q, Lu X, Zhao C, Liao S, Chen X, Guo F, et\u00a0al. Metformin: the updated protective property in kidney disease. Aging (Albany NY). 2020;12:8742\u201359.","journal-title":"Aging (Albany NY)"},{"key":"4136_CR13","first-page":"621","volume":"17","author":"FG Amini","year":"2012","unstructured":"Amini FG, Rafieian-Kopaei M, Nematbakhsh M, Baradaran A, Nasri H. Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. J Res Med Sci. 2012;17:621\u20135.","journal-title":"J Res Med Sci"},{"key":"4136_CR14","first-page":"21","volume":"4","author":"BL McDaniel","year":"2015","unstructured":"McDaniel BL, Bentley ML. The role of medications and their management in acute kidney injury. Integr Pharm Res Pract. 2015;4:21\u20139.","journal-title":"Integr Pharm Res Pract"},{"key":"4136_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/j.1552-4604.1995.tb04033.x","volume":"35","author":"NC Sambol","year":"1995","unstructured":"Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et\u00a0al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094\u2013102.","journal-title":"J Clin Pharmacol"},{"key":"4136_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246247","volume":"16","author":"IHS Kuan","year":"2021","unstructured":"Kuan IHS, Wilson LC, Leishman JC, Cosgrove S, Walker RJ, Putt TL, et\u00a0al. Metformin doses to ensure efficacy and safety in patients with reduced kidney function. PLoS ONE. 2021;16: e0246247.","journal-title":"PLoS ONE"},{"key":"4136_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/bdd.564","volume":"28","author":"YH Choi","year":"2007","unstructured":"Choi YH, Lee I, Lee MG. Effects of water deprivation on the pharmacokinetics of metformin in rats. Biopharm Drug Dispos. 2007;28:373\u201383.","journal-title":"Biopharm Drug Dispos"},{"key":"4136_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2169\/internalmedicine.36.102","volume":"36","author":"N Tsuboi","year":"1997","unstructured":"Tsuboi N, Yoshida H, Shibamura K, Hikita M, Tomonari H, Kuriyama S, et\u00a0al. Acute renal failure after binge drinking of alcohol and nonsteroidal antiinflammatory drug ingestion. Intern Med. 1997;36:102\u20136.","journal-title":"Intern Med"},{"key":"4136_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3122\/15572625-11-3-233","volume":"11","author":"DT Hulisz","year":"1998","unstructured":"Hulisz DT, Bonfiglio MF, Murray RD. Metformin-associated lactic acidosis. J Am Board Fam Pract. 1998;11:233\u20136.","journal-title":"J Am Board Fam Pract"},{"key":"4136_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5414\/CNP66380","volume":"66","author":"H Gudmundsdottir","year":"2006","unstructured":"Gudmundsdottir H, Aksnes H, Heldal K, Krogh A, Froyshov S, Rudberg N, et\u00a0al. Metformin and antihypertensive therapy with drugs blocking the renin angiotensin system, a cause of concern? Clin Nephrol. 2006;66:380\u20135.","journal-title":"Clin Nephrol"},{"key":"4136_CR21","doi-asserted-by":"publisher","first-page":"17923","DOI":"10.1073\/pnas.0506483102","volume":"102","author":"M Otsuka","year":"2005","unstructured":"Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005;102:17923\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4136_CR22","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1681\/ASN.2006030205","volume":"17","author":"S Masuda","year":"2006","unstructured":"Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, Inui K. Identification and functional characterization of a new human kidney-specific H+\/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17:2127\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"4136_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/clpt.2012.210","volume":"93","author":"SL Stocker","year":"2013","unstructured":"Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, et\u00a0al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93:186\u201394.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04136-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04136-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04136-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T16:46:24Z","timestamp":1700325984000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04136-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,16]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4136"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04136-0","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,16]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In Japan, a case report does not require ethics approval. The study adhered to the Ethical Guidelines for Medical and Health Research Involving Human Subjects established by the government of Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"393"}}